Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,041 to 2,060 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Retraction Notice to: METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing. | Mol Ther | 2022 | 35797982 | PubTator, text mining | PubMed |
| Progress and application of epitranscriptomic m6A modification in gastric cancer. | RNA Biol | 2022 | 35796515 | PubTator, text mining | PubMed |
| mRNAs sequestered in stress granules recover nearly completely for translation. | RNA Biol | 2022 | 35796440 | PubTator, text mining | PubMed |
| N 6-Methyladenosine Methylomic Landscape of Ureteral Deficiency in Reflux Uropathy and Obstructive Uropathy. | Front Med (Lausanne) | 2022 | 35795641 | PubTator, text mining | PubMed |
| Immune Infiltration of Ulcerative Colitis and Detection of the m6A Subtype. | J Immunol Res | 2022 | 35795532 | PubTator, text mining | PubMed |
| Predictive Potentials of ZEB1-AS1 in Colorectal Cancer Prognosis and Their Correlation with Immunotherapy. | J Oncol | 2022 | 35794981 | PubTator, text mining | PubMed |
| Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. | J Hematol Oncol | 2022 | 35794625 | PubTator, text mining | PubMed |
| The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma. | J Transl Med | 2022 | 35794583 | PubTator, text mining | PubMed |
| Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types. | Exp Mol Med | 2022 | 35794212 | PubTator, text mining | PubMed |
| A bioinformatic analysis study of m7G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma. | BMC Cancer | 2022 | 35788194 | PubTator, text mining | PubMed |
| The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research. | Front Pharmacol | 2022 | 35784761 | PubTator, text mining | PubMed |
| Genome-Wide Identification of N6-Methyladenosine Associated SNPs as Potential Functional Variants for Type 1 Diabetes. | Front Endocrinol (Lausanne) | 2022 | 35784577 | PubTator, text mining | PubMed |
| Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. | Front Immunol | 2022 | 35784363 | PubTator, text mining | PubMed |
| Crosstalk Between Histone and m6A Modifications and Emerging Roles of m6A RNA Methylation. | Front Genet | 2022 | 35783260 | PubTator, text mining | PubMed |
| Williams-Beuren Syndrome Related Methyltransferase WBSCR27: From Structure to Possible Function. | Front Mol Biosci | 2022 | 35782865 | PubTator, text mining | PubMed |
| N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. | BMC Cancer | 2022 | 35778697 | PubTator, text mining | PubMed |
| The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer. | Medicine (Baltimore) | 2022 | 35777046 | PubTator, text mining | PubMed |
| Alterations of RNA Modification in Mouse Germ Cell-2 Spermatids Under Hypoxic Stress. | Front Mol Biosci | 2022 | 35775084 | PubTator, text mining | PubMed |
| Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer. | Dis Markers | 2022 | 35774851 | PubTator, text mining | PubMed |
| HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency. | Front Cell Infect Microbiol | 2022 | 35774399 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=103